The RGS1 gene is associated with celiac disease, multiple sclerosis, and type I diabetes, which are all T cellmediated pathologies, yet there is no reported analysis of regulator of G protein signaling (RGS)1 biology in human T cells. This study shows that RGS1 expression is substantially higher in T cells from human gut versus peripheral blood and that this can be exaggerated in intestinal inflammation. Elevated RGS1 levels profoundly reduce T cell migration to lymphoid-homing chemokines, whereas RGS1 depletion selectively enhances such chemotaxis in gut T cells and impairs their colitogenic potential. These findings provide a revised framework in which to view the linkage of RGS1 to inflammatory disease. The Journal of Immunology, 2011, 187: 2067-2071.
F
or T cells to make regulated responses to infections within tissues, they must enter, reside within, and then egress from relevant sites. Chemokines play pivotal roles in such processes. In chronic inflammation, it may be argued that T cell egress in response to lymphoid-homing chemokines is impaired; hence the value of elucidating the factors regulating the selective chemotaxis of T cells. Being Gprotein coupled receptors, chemokine receptors may be regulated by regulator of G-protein signaling (RGS) molecules that bind Ga proteins, increasing their intrinsic GTPase activity up to 100-fold and, thereby, attenuating signaling (1). Rgs1 mRNA is highly enriched in murine gut versus lymphoid T cells (2) (3) (4) , suggesting that it might likewise be enriched in human gut T cells where it might selectively regulate chemokine responses. However, although RGS1 was shown to regulate B cell chemotaxis, there has been no substantive study of it in human T cells.
Perhaps discouraging such analysis, splenic and lymph node T cells from Rgs1 2/2 mice show seemingly normal chemotaxis (5) . Nonetheless, the strong associations of RGS1 single nucleotide polymorphisms (SNPs) with T cell-mediated diseases, including type 1 diabetes, celiac disease, and multiple sclerosis (4, (6) (7) (8) , argue for it being an important T cell regulator. Therefore, this study investigates RGS1 biology in human intestinal T cells, with supporting studies of Rgs1
mice. The data argue for a pivotal role for RGS1 in T cell trafficking and tissue immunopathologies.
Materials and Methods

Human samples
Mucosal biopsies and paired blood samples were taken from patients, with their consent, who had ulcerative colitis (UC) or Crohn's disease (CD) and were undergoing ileocolonoscopy or from control patients undergoing colonoscopy for polyp follow-up or diagnosis. PBMCs were isolated using Ficoll (GE Healthcare), and gut intraepithelial lymphocytes and lamina propria lymphocytes were isolated, as described (9) . Cells were stained and flow sorted into discrete populations. RNA was isolated; cDNA synthesis was performed; and RGS1, RGS2, and RGS10 mRNA were assayed by quantitative RT-PCR relative to cyclophilin A, using the following primers: RGS1: 59-TGTGCATTCAGATGCTGCTA-39 and 59-CTCGAGTGCGGAAGT-CAATA-39; RGS2: 59-AAGATTGGAAGACCCGTTTG-39 and 59-GA-TGAAAGCTTGCTGTTTGC-39; RGS10: 59-CCCTGGAGAATCTGCT-GGAAC-39 and 59-TTTCCTGCATCTGAGTCTTA-39; and cyclophilin A: 59-TGGTGGACCCAACACAAATC-39 and 59-TGCCATCCAACCACTCA-GTCT-39.
Mice
Wild-type (WT) and Rgs1 2/2 C57BL/6 mice have been described (5) 
Transient transfections
Jurkat cells were transiently transfected with internal ribosome entry site (IRES)-enhanced GFP (EGFP) (Clontech) or RGS1-EGFP by electroporation, alone or with CCR7-tomato (pMIT-tomato; kind gift of H. Jumaa, Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany). Cells were left for 24-48 h and washed before use. Primary human T cell blasts were transfected with IRES-EGFP, RGS1-EGFP, or RGS10-EGFP (B isoform), using Amaxa II nucleofection.
Migration assays
Transfected Jurkat cells were placed in Transwell-migration assays (5 mM pore; Corning) for 2-3 h at 37˚C, and migrated cells were enumerated by FACS Canto II (BD) analysis of 150 ml harvested from the bottom chamber. Cells migrated to 200 ng/ml human CXCL12 (ImmunoTools) or 500 ng/ml human CCL19 (R&D Systems). Percentages of migrated cells were calculated by dividing the number of transmigrated EGFP hi , EGFP low , or EGFP 2 cells by the number of input cells with comparable EGFP levels. Murine intestinal T cells were isolated and placed in Transwell-migration assays, and migrated cells (CD45 + , TCR + ) were enumerated as above in response to recombinant murine CCL19 (50 ng/ml), CCL20 (50 ng/ml), CXCL12 (100 ng/ml; all from ImmunoTools), or CCL25 (50 ng/ml; R&D Systems).
Confocal imaging
Transfected primary human T cell blasts were incubated overnight, washed, and equilibrated on an ICAM-1-precoated mVI slide (Ibidi, Munich, Germany). A total of 2 3 10 5 cells was added to each slide chamber and imaged every 10 s for 20 min. Prior to image acquisition, 10 ml medium or recombinant human CXCL12 (10 mg/ml; R&D Systems) was applied to filter paper at one end of the chamber. Time-lapse films were analyzed by Volocity (Improvision, Coventry, U.K.), and EGFP + cells were tracked automatically.
Results and Discussion
RGS1 overexpression in normal and inflamed gut
To determine whether human intestinal T cells, like their mouse counterparts, are enriched in RGS1 expression, RGS1 RNA was quantified in purified TCRab + CD4 + and TCRab + CD8ab + cells from peripheral blood (light diamonds) or gut biopsies (dark diamonds) (Fig. 1A) . Notwithstanding interindividual variation common in human studies, RGS1 was overexpressed in human gut T cells by an average of ∼100-fold, as occurs in mice (2-4). RGS2 was overexpressed less overtly (∼15-fold), and RGS10 was generally underrepresented in gut T cells (Supplemental Fig. 1A , 1B), again as is true in mice. RGS1 can regulate B cell migration to chemokines by targeting Ga i (10), whereas RGS2 preferentially targets Ga q (11), which is not commonly used by chemokine receptors. Hence, RGS1 became the primary focus for further studies.
Conventional (CD4 + ; CD8ab + ) and pooled unconventional (CD4 2 CD8 2 double negative and CD4 2 CD8aa + ) ab T cells from normal, CD, and UC gut mucosa (Fig. 1B) revealed consistently high RGS1 levels; although many CD/ UC samples fell within the normal range, some showed highly elevated expression, particularly for intestinal CD4 + T cells (p , 0.04). This is noteworthy, given that many such cells will have infiltrated the inflamed gut from the blood and lymphoid organs where RGS1 levels are low (Fig. 1A) . Although such cells will be activated in the gut, activation alone of peripheral blood T cells evoked only a transient increase in RGS1 RNA, with peak levels ∼10-fold less than in gut T cells (Supplemental Fig. 1C) . Moreover, RGS1 expression was not significantly different in naive versus memory CD4 T cells (Supplemental Fig. 1D ).
RGS1 decreases T cell migration to lymphoid-homing chemokines
To assess the functional significance of RGS1 overexpression, Transwells were used to assay T cell migration to chemokines. Because two human RGS1 transcripts, differing in coding potential by 13 aa, have been reported (5), Jurkat cells, which do not express RGS1, were independently transfected with each species linked via an IRES to EGFP. Relative to control, EGFP + empty-vector transfectants, EGFP + RGS1 transfectants showed dose-dependent inhibition of migration to CXCL12, a lymphoid chemokine for the receptor CXCR4. Moreover, transfectants expressing lower levels of RGS1 (EGFP low ) were less compromised than were EGFP hi cells expressing higher RGS1 (Fig. 2A) . From data collated from 10 independent experiments, RGS1 significantly decreased migration to CXCL12 by .35% (p , 0.01). Primary human peripheral blood T cells, which express very little RGS1, were engineered to overexpress either RGS1 or RGS10, and their migration was assessed by time-lapse microscopy ( Fig. 2B) . Addition of CXCL12 to the bottom of the ICAM-1-coated slide redirected the random migration of empty-vector control or RGS10-transfected cells along the chemokine gradient (Fig. 2B) , with coincident decreases in migration velocity (p ∼ 0.001; Fig. 2C ). Conversely, RGS1-transfected cells did not align with the chemokine gradient (Fig. 2B, 2C) . Thus, increasing RGS1 limited CXCL12 responsiveness without grossly affecting normal kinesis.
To assess the capacity of RGS1 to regulate CCR7-mediated chemotaxis to CCL19, which promotes T cell egress from tissues to lymph nodes, Jurkat cells (which express very low levels of CCR7) were transfected with CCR7 (upstream of a tomato-tracker gene), resulting in CCR7 surface expression (Fig. 2D ) and migration to CCL19 (Fig. 2E) . Cotransfection with RGS1 did not effect CCR7 levels (Fig. 2D ), but across 10 independent experiments it reduced migration to CCL19 by ∼54% (p , 0.003) (Fig. 2E) .
Having established that RGS1 is elevated in human gut T cells and can limit directional chemotaxis, the requirement for RGS1 in T cell migration was re-examined. Of note, the comparable migration to CCL19 reported for WT and Rgs1 2/2 splenic T cells (5) might simply reflect the negligible expression of RGS1 by splenic T cells. Consistent with this, intestinal T cells from Rgs1 2/2 mice showed significantly enhanced migration to CCL19 and CXCL12 relative to WT intestinal T cells. By contrast, migration to the gut-homing chemokine CCL25 (CCR9 ligand) or to CCL20 (CCR6 ligand) was not affected (Fig. 3) . Hence, RGS1 specifically limited gut T cell responsiveness to the lymphoid-homing chemokines tested. Also, in two animal housing facilities, the gut-associated integrin, CD103, was found on significantly more CD4 + T cells (p , 0.008) (Supplemental Fig.  2A ) at significantly higher levels (p , 0.037) in the spleens of Rgs1 2/2 mice versus WT mice, perhaps reflecting enhanced intestinal egress.
To determine whether these effects extrapolated to a role for Rgs1 in intestinal immunopathology, three experiments in two animal housing facilities on two continents compared the colitogenic potentials of Rgs1 2/2 versus WT T cells after transfer to Rag2 2/2 mice (12). Invariably, colitis was ameliorated by Rgs1 deficiency, as judged by a significantly reduced increase in colon weight/thickness and by histopathology (Fig.  4A-C) . Recipients of Rgs1 2/2 cells usually lost less weight (Supplemental Fig 2B) , although, as noted previously (13), overall weight loss does not correlate well with colitis in this system. Reduced disease did not reflect generally impaired engraftment, because in contrast to the gut, spleens of recipient mice showed comparable accumulation of Rgs1 2/2 and WT T cells (Supplemental Fig. 2C ).
In sum, this first study of RGS1 biology in human T cells identified overtly high expression in the gut; exaggerated expression in some cases of inflammatory bowel disease (IBD); a significant, nonredundant capacity to limit gut T cell responses to lymphoid-homing chemokines; and a profound contribution to the colitogenic potential of T cells. These findings could be consistent with RGS1 ordinarily repressing T cell egress from the gut, possibly to sustain local immunoprotection and/or immunoregulation vis-à-vis commensals. Nonetheless, an analogous capacity to limit egress of inflammatory and/or autoimmune cells could clearly promote immunopathology. Such a key contribution of regulated T cell migration to pathology seems consistent with spontaneous colitis occurring in mice lacking Ga i2 , which reportedly opposes the effects of RGS1 in B cells (14, 15) . Additionally, the selective importance of RGS1 is strongly suggested by evidence that mice transgenic for Rgs16, which does not affect responses to CCL19 (16, 17) and which is not substantively expressed in the gut (data not shown), display T cell hyperresponsiveness (as do Ga i2 mutant mice) but no colon pathology.
Notwithstanding practical difficulties, it would seem appropriate to assess whether RGS1 is elevated in relevant tissueassociated T cells in type 1 diabetes, multiple sclerosis, and celiac disease, all of which are associated with RGS1 SNPs (4, (6) (7) (8) . That such SNPs have not been associated with IBD may merely reflect the complex, multifactorial nature of IBD and should not diminish the prospect of RGS1 regulating disease initiation and/or progression. Indeed, RGS1 has been highlighted as a biomarker for undifferentiated spondyloarthritis (18) , often associated with gastrointestinal lesions (19) . Clearly, RGS1 seems to be a valid, tissue-associated target for further biological and clinical investigation. 2/2 mice were injected in three separate experiments with either PBS (n = 6) or CD4 + CD45RB hi T cells extracted from WT (n = 13) or Rgs1 2/2 mice (n = 11). Colons were removed 7-8 wk later, weighed, and sectioned. Mean colon weight (A) and medial colon thickness (B) in recipients of WT or Rgs1 2/2 T cells or PBS. Statistics were calculated using the Student t test. C, Representative mid-colon histologies for recipients of WT cells (left panels) or Rgs1 2/2 cells (right panels). One colon for each group is shown from each of three independent experiments, stained with H&E. Scale bars, 500 mm.
